ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | 0.19 | -0.06 | 0.24 |
| FCF Yield | -2.96% | -3.45% | -3.39% | -4.65% |
| EV / EBITDA | -65.09 | -46.06 | -31.21 | -55.78 |
| Quality | ||||
| ROIC | 0.00% | -19.87% | -24.55% | -20.69% |
| Gross Margin | 87.12% | 99.49% | 99.65% | 100.00% |
| Cash Conversion Ratio | 1.02 | 0.86 | 0.66 | 1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 429.53% | 357.26% | 276.29% | 294.59% |
| Free Cash Flow Growth | 14.75% | 7.12% | 0.26% | 14.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -6.68 | -4.79 | -8.99 |
| Interest Coverage | -2.02 | -2.47 | -2.23 | -4.66 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.02 | 0.01 | 0.00 |
| Cash Conversion Cycle | 0.00 | -439.46 | -7,751.97 | 31.62 |